Research terms & Most Important Terms and Conditions
Read the official mandatory terms and standardised MITC in Annexure B. Signed or otherwise legally acceptable consent is required; consent is not inferred from browsing or account creation.
Clause 28(ii)(b) removes the signature-consent requirement for institutional investors and qualified institutional buyers, while retaining terms/MITC disclosure. This portal applies an explicit acknowledgement gate to all research accounts as its onboarding policy; it is not presented as a universal statutory signature requirement.
| Subject | What the client must receive or understand |
|---|---|
| Scope & obligations | Research is chosen voluntarily for the client's own use. Both parties remain bound by applicable SEBI law. The RA cannot execute purchase/sale transactions on the client's behalf. |
| Identity & declarations | Registered name, number/date, valid qualifications/registration, independence and other-activity declarations, and compliance with applicable law must be confirmed by the RA, not inferred. |
| KYC | Provide complete current identity/contact information and supporting records; fee-paying client KYC/KRA checks must be completed as prescribed. |
| Fee ceiling | Clause 1.9 specifies Rs 1,51,000 per annum per family for non-accredited individual/HUF clients, excluding statutory charges and subject to any later RAASB-announced revision. Non-individual/accredited-client terms are bilaterally negotiated. The exact agreed fee must be disclosed before consent. |
| Advance fees | Client agreement is required. Clause 1.9(f), reflecting the 2 April 2025 circular, permits up to one year; the reproduced MITC in Annexure B retains a one-quarter reference. The RA must resolve this wording with RAASB/legal review in the approved agreement before collecting advance fees. Checkout is not enabled here. |
| Payment | Only authorised banking/payment channels such as cheque, bank transfer or UPI; no cash. CeFCoM managed by BSE is an optional fee mechanism, not a compulsory payment route. Verify the beneficiary and current validated payment instructions. |
| Risks & no guarantee | Market, liquidity, volatility, concentration, issuer and model/assumption risks can cause losses. Research cannot guarantee returns, profits, accuracy or risk-free outcomes. Investment losses from relying on research are not recoverable merely because the recommendation did not succeed; statutory rights concerning misconduct or service deficiency remain available. |
| Conflicts & AI | Disclose/mitigate actual and potential conflicts, associates and other activities; explain the extent of AI use at onboarding and when it changes. Human approval does not remove the required AI-use disclosure or the RA's responsibility for data and outputs. |
| Termination & refunds | Premature termination requires proportionate refund for the unexpired period, with no breakage fee for covered individual/HUF clients. Suspension exceeding 60 days or cancellation requires the prescribed pro-rata refund from its effective date. |
| Grievances | Provide named contacts and escalation channels. Annexure B specifies seven business working days for service-deficiency complaints; the Charter also sets the outer 21-day redressal timeline. SCORES and SMART ODR remain available. |
| Changes & continuing duties | Additional voluntary clauses cannot contravene SEBI requirements; give 15 days' notice before changes to such clauses. Keep contact details updated and refer to the Charter's do's/don'ts. |
Before paying, verify the registered intermediary's bank/validated UPI details using SEBI's payment-verification facility where applicable. See the official validated-UPI circular referenced in clause 26 and SEBI Check launch guidance. No unverified beneficiary, QR code or payment address is published here.
Regulatory source: SEBI Master Circular for Research Analysts, 6 February 2026. This Research Analyst framework does not confer Investment Adviser registration. Accessibility assistance and outstanding accessibility review.
